Learn how to achieve truly patient-focused drug development while gaining deeper insights from patients in your clinical trials.
What does the FDA’s new draft guidance on patient experience data mean for your clinical development and launch strategy?
Our expert panel will discuss the new draft guidance and its impact on product development and marketing. You’ll hear how to deliver qualitative insights as part of clinical development — while maintaining regulatory compliance.
You’ll learn about:
- Benefits to the pharmaceutical company
- Regulatory issues to be addressed
- A stepwise process for implementation of greater patient-centricity
Who should attend:
- Market Research
- Medical Affairs
- Health Economics
- Clinical Development
The Panel Members
Director, Global Patient Solutions Insight, Teva (former)
Vice President, Client Services, Kinetiq Consulting, a Division of Quorum Review IRB
PharmD, MBAManaging Director and Founder, Clinical SCORE